Antara AGEasy celebrates one year of advancing senior health solutions

AGEasy has made significant strides in addressing the pressing health concerns of seniors in India

Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV

Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr

Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs

Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years

Atul Bioscience received EIR from USFDA for Ambernath facility

The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations